MiMedx Q2 FY26 net loss widens to $14.84 million; net sales drop 34.7% to $64.36 million

• MiMedx posted a GAAP net loss of USD 14.84 million, or USD 0.10 per diluted share, for the quarter ended June 30, 2026.
• Net sales fell 34.7% to USD 64.36 million versus the prior-year quarter.
• Surgical net sales rose 15.1% to USD 39.3 million, while Wound net sales dropped 61.1% to USD 25.07 million.
• Gross margin narrowed 12.1 percentage points to 69.0%.
• Completed a reduction-in-force and other cost actions; repurchased about USD 13 million of stock, ending the quarter with USD 135.8 million in cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiMedx Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001376339-26-000071), on July 29, 2026, and is solely responsible for the information contained therein.